# Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis

> **NCT01443364** · PHASE4 · COMPLETED · sponsor: **UCB Italy s.p.a.** · enrollment: 132 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** Certolizumab pegol

## Key facts

- **NCT ID:** NCT01443364
- **Lead sponsor:** UCB Italy s.p.a.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2017-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01443364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01443364, "Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01443364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*